NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
11 trialsNCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02335983 2020-11-06
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Amgen
Phase 1 Completed
NCT01738594 2019-08-29
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
Phase 1 Terminated
NCT01980589 2017-05-30
CHAMPION 2
Amgen
Phase 1 Completed
NCT00150462 2017-05-02
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Amgen
Phase 1 Completed
NCT01949532 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Amgen
Phase 1 Completed
NCT01949545 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Amgen
Phase 1 Completed